Research programme: antimalarials - Novartis and collaborators

Drug Profile

Research programme: antimalarials - Novartis and collaborators

Alternative Names: Imidazolopiperazines - Novartis; Imidazopyrazines - Novartis; Spiroindolones - Novartis

Latest Information Update: 04 Dec 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Class Carbolines; Imidazoles; Imidazolines; Piperazines; Pyrazines; Spiro compounds
  • Mechanism of Action 1-phosphatidylinositol 4-kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Malaria

Most Recent Events

  • 28 Nov 2013 Preclinical development is ongoing
  • 18 Nov 2011 Preclinical development is ongoing
  • 03 Sep 2010 Lead compound, NITD 609, identified from the programme
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top